BioNucleon is a spin-off of the Institute of Biostructure and Bioimaging (IBB) of the Italian National Research Council, which is based at the University “Federico II” of Naples, and belongs to the Eporgen Venture portfolio of companies

BioNucleon’s research is centered on proprietary oligonucleotide-based ligands for cancer-related targets, with the aim to develop novel anti-cancer therapies with an improved safety profile.

BioNucleon’s innovative lead compound (BN210) targets the Hepatoma Related Protein 3 (HRP-3) and has successfully reached pre-clinical proof of concept in neuroblastoma.

BioNucleon is currently seeking a partnership with an oncology franchise for the future development of BN210 and of other compounds from the class